Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001

Sponsor
Gerhard Treiber
Study ID
NCT00775073
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Everolimus, Bevacizumab — DRUG
    Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.

Study Details

This is a prospective open label clinical trial in patients with advanced or metastatic liver cancer to assess the clinical and biological activity of RAD001 (Everolimus) in conjunction with Bevazicumab (Avastin). Approximately 36 patients will be enrolled.

Key Dates

First listed
Oct 17, 2008
Start date
Oct 31, 2008
Status verified
Apr 2012
Primary completion
Jan 31, 2011
Completion
Apr 30, 2012

Study Design

Enrollment
33 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Bevacizumab (Avastin) \& Everolimus (RAD001)

Primary Outcome Measure

Time to Progression [ Time Frame: 24 and 48 weeks ]

Related Studies